DOCSLIB.ORG

Tetrahydrobiopterin Improves Endothelium-Dependent Vasodilation by Increasing Nitric Oxide Activity in Patients with Type II Diabetes Mellitus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tetrahydrobiopterin Improves Endothelium-Dependent Vasodilation by Increasing Nitric Oxide Activity in Patients with Type II Diabetes Mellitus Diabetologia 2000) 43: 1435±1438 Ó Springer-Verlag 2000 Short communication Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus T.Heitzer, K.Krohn, S.Albers, T.Meinertz University Hospital Clinic Hamburg-Eppendorf, Department of Cardiology, Clinic for Internal Medicine, Hamburg, Germany Abstract line and sodium nitroprusside. In contrast, in diabetic patients, the attenuated endothelium-dependent va- Aims/hypothesis. Tetrahydrobiopterin is an essential sodilation to acetylcholine was considerably im- cofactor of nitric oxide synthase, and its deficiency proved by concomitant treatment with tetrahydrobi- decreases nitric oxide bioactivity. Our aim was to opterin, whereas the endothelium-independent va- find whether supplementation of tetrahydrobiopterin sodilation was not affected. This beneficial effect of could improve endothelial dysfunction in diabetic pa- tetrahydrobiopterin in diabetic patients could be tients. completely blocked by NG-monomethyl-l-arginine. Methods. Forearm blood flow responses to the endo- Conclusion/interpretation. These findings suggest the thelium-dependent vasodilator acetylcholine 0.75± possibility that endothelial dysfunction in Type II dia- 3.0 mg ´ 100 ml±1 ´ min±1) and to the endothelium- betes might be related to decreased availability of independent vasodilator sodium nitroprusside tetrahydrobiopterin. [Diabetologia 2000) 43: 1435± 0.1±1.0 mg ´ 100 ml±1 ´ min±1) before and during con- 1438] comitant intra-arterial infusion of tetrahydrobiopter- in 500 mg/min) were measured by venous occlusion Keywords Diabetes mellitus, endothelium, nitric ox- plethysmography in 12 control subjects and 23 pa- ide, tetrahydrobiopterin, endothelium-dependent va- tients with Type II non-insulin-dependent) diabetes sodilation, acetylcholine, NG-monomethyl-l-arginine. mellitus. Results. In control subjects, tetrahydrobiopterin had no effect on the dose-response curves to acetylcho- The endothelium has a pivotal role in maintaining mellitus is associated with endothelial dysfunction. vascular tone and function and is intimately involved The exact mechanisms are not known but decreased in the pathogenesis of atherosclerosis. Experimental synthesis of nitric oxide NO) or increased inactiva- and clinical investigations have shown that diabetes tion of NO by oxygen free radicals have both been proposed. Recent reports have shown that exogenous treatment with tetrahydrobiopterin improves im- Received: 25 May 2000 and in revised form: 14 July 2000 paired NO bioactivity in patients with hypercholes- terolaemia [1] and heavy smokers [2]. Notably, in vit- Corresponding author: T. Heitzer, Universitätsklinikum Ham- ro studies with aortic rings of diabetic rats showed burg-Eppendorf, Klinik und Poliklinik für Innere Medizin, restoration of endothelial function after pre-incuba- Abteilung Kardiologie, Martinistr. 52, 20246 Hamburg, Ger- tion with tetrahydrobiopterin BH4) [3]. Tetrahydro- many biopterin is a critical cofactor for NO formation and Abbreviations: NO, Nitric Oxide; NOS, nitric oxide synthase; ACh, acetylcholine; SNP, sodium nitroprusside; l-NMMA, seems to modulate nitric oxide synthase NOS) activ- NG-monomethyl-l-arginine; FBF, forearm blood flow; BH4, ity. In the absence of sufficient BH4, NOS changes its tetrahydrobiopterin. functional profile: instead of oxidizing l-arginine, the 1436 T.Heitzer et al.: Tetrahydrobiopterin and endothelial dysfunction Table 1. Clinical characteristics of study groups 30 min, tetrahydrobiopterin BH4 500 mg/min, Schircks labo- ratories, Iona, Switzerland) was given to all study participants Diabetic Control patients subjects to test the effects of BH4 on FBF response to ACh and sodium nitroprusside SNP). This dose of BH4 was chosen to reach n 23 12 plasma concentrations that have been shown to achieve maxi- Sex male/female) 16/7 8/4 mum NO production by NOS in vitro [7] and to improve en- Age years) 52 2 50 3 dothelium-dependent vasodilation in patients with hypercho- Duration of diabetes years) 5.3 0.6 ± lesterolaemia [1] and heavy smokers [2]. Subsequently, the 2 a BMI kg/m ) 27.4 0.4 24.7 0.6 dose-response curve to ACh was repeated during co-infusion HbA %) 7.8 0.2a 5.4 0.2 1c of BH4 and l-NMMA. Fasting glucose mmol/l) 9.4 0.6a 4.9 0.1 Total cholesterol mmol/l) 5.3 0.2 5.4 0.4 LDL-cholesterol mmol/l) 3.3 0.2 3.4 0.3 Statistical analysis. All values are reported as means SEM. HDL-cholesterol mmol/l) 1.1 0.06 1.2 0.05 Group comparisons with baseline characteristics were done Triglycerides mmol/l) 2.1 0.2a 1.4 0.3 by unpaired t test. Responses to ACh, SNP and l-NMMA, Mean blood pressure mm Hg) 92 3a 88 4 with and without BH4, were analysed by ANOVA for repeat- Forearm volume liter) 1.02 0.03 1.08 0.09 ed measures and Scheffe's test was applied for multiple com- Forearm blood flow 2.8 0.1 2.9 0.2 parison testing. A value of p < 0.05 was considered statistically ml 100 ml±1 min±1) significant. Data presented as means SEM. a p < 0.05 vs control subjects Results enzyme reduces molecular oxygen to superoxide an- ion, even in the setting of adequate substrate concen- The clinical characteristics of the study groups are tration [4]. An abnormal metabolism of tetrahydrobi- provided in Table 1. The diabetic patients and control opterin has recently been found to be the major cause subjects were matched for age. The serum cholesterol of impaired endothelium-dependent relaxation concentrations were similar in both groups. Diabetic ± through nitric oxide/O2 imbalance in aorta of insu- subjects had statistically significantly higher fasting lin-resistant rats [5]. glucose, glycated haemoglobin, body mass index, The intention of our study was therefore to assess mean blood pressure and triglyceride concentrations. whether BH4 could improve the endothelial dysfunc- Forearm volume and basal forearm blood flow were tion of patients with Type II non-insulin-dependent) similar between diabetic and control subjects. diabetes mellitus. Acetylcholine dose-dependently increased FBF in both groups Fig.1). The vasodilator responses to ACh were statistically significantly attenuated in dia- ±1 Subjects and methods betic patients maximum FBF: 9.8 1.0 ml ´ 100 ml ´ min±1) compared with control subjects maximum FBF: 18.3 1.1 ml ´ 100 ml±1 ´ min±1). Co-infusion of Subjects. We studied twelve control subjects and 23 patients with Type II diabetes Table 1). Glycaemic control was the NOS-inhibitor, l-NMMA, blunted the ACh-in- achieved by diet alone n = 7) or diet plus oral hypoglycaemic duced vasodilation statistically significantly in control agents n = 16) metformin or sulphonylureas or both). The subjects. In diabetic patients, l-NMMA had, howev- criteria for exclusion of both diabetic and control subjects in- er, no significant effect. Infusion of BH4 did not cluded hypertension > 145/90 mmHg), increased LDL-cho- change basal FBF in either group. In control subjects, lesterol > 75th centile for age and sex), cardiac or cerebrovas- co-infusion of BH4 had no effect on ACh-induced va- cular disease, renal impairment and the habit of smoking. Fur- ther exclusion criteria were current use of insulin, antioxidants sodilation. In diabetic patients, ACh-induced vasodi- or hormone replacement therapy. All female subjects were lation was, however, statistically significantly en- postmenopausal. Forearm volume was measured according to hanced by concomitant BH4 treatment maximum the water displacement method. Informed consent was ob- FBF: 15.1 1.2 ml ´ 100 ml±1 ´ min±1). When the effect tained from all subjects, and the study was approved by the lo- of l-NMMA was re-tested in the presence of BH4, cal ethics committee. the NOS-inhibitor completely abolished the vasodila- tory effect of BH4 in diabetic patients maximum Study protocol. Forearm blood flow FBF) was measured by ±1 ±1 venous occlusion plethysmography as described recently [2, FBF: 8.9 1.1 ml 100 ml ´ min ). In control sub- 6]. Endothelium-dependent vasodilation was assessed by in- jects, BH4 did not alter the inhibitory effect of l- fusing acetylcholine ACh, Farmigea, Pisa, Italy) in increasing NMMA on the ACh dose-response curve. concentrations of 0.75, 1.5 and 3.0 mg ´ 100 ml forearm tis- The FBF response to SNP was no different be- sue±1 ´min±1 into the brachial artery. Sodium nitroprusside tween diabetic patients maximum FBF: 14.3 SNP; Schwarz Pharma, Monheim, Germany) was infused to 1.1 ml ´ 100 ml±1 ´ min±1) and control subjects maxi- assess endothelium-independent vasodilation 0.1, 0.3 and mum FBF: 14.7 1.2 ml ´ 100 ml±1 ´ min±1) and was 1.0 mg ´ 100 ml forearm tissue±1 ´min±1). During coinfusion of NO-synthase inhibitor NG-monomethyl-l-arginine l-NMMA not modified by BH4 diabetic patients: maximum 8 mmol/min, Calbiochem, Bad Soden, Germany), the acetyl- FBF 14.7 1.2 ml ´ 100 ml±1 ´ min±1; control subjects: choline ACh) response curve was repeated. After a rest of maximum FBF: 14.4 1.1 ml ´ 100 ml±1 ´ min±1). T.Heitzer et al.: Tetrahydrobiopterin and endothelial dysfunction 1437 AB Fig.1A, B. Effect of tetrahydrobiopterin BH4) on acetylcho- showed increased formation of free radical-catalysed line-induced vasodilation in diabetic patients A) and control products of arachidonic acid such as 8-epi-PGF2a in subjects B) with and without co-infusion of l-NMMA. Tetra- patients with diabetes [8]. Furthermore, endotheli- hydrobiopterin significantly improved acetylcholine-induced vasodilation in diabetic patients, but did not change the dose- um-dependent vasodilation could be restored in pa- response curve in control subjects. In diabetic patients, co-in- tients with non-insulin-dependent diabetes by short- fusion of l-NMMA had no effect under control conditions sa- term treatment wtih the antioxidant vitamin C [6]. line) but completely blocked the BH4-induced increase in Tetrahydrobiopterin is an important cofactor for forearm blood flow. In control subjects, the effect of l- NOS and seems to determine whether the electron NMMA on the dose-response curve was not altered by BH4.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia
    003 1-399819113005-0435$03.00/0 PEDIATRIC RESEARCH Vol. 30, No. 5, 1991 Copyright 0 199 1 International Pediatric Research Foundation, Inc. Pr~ntc.d in U.S. A Tetrahydrobiopterin Loading Test in Hyperphenylalaninemia ALBERT0 PONZONE, ORNELLA GUARDAMAGNA, SILVIO FERRARIS, GIOVANNI B. FERRERO, IRMA DIANZANI, AND RICHARD G. H. COTTON InstiflifeofPediatric Clinic(A.P., O.G., S.F., G.B.F., I.D.], University of Torino, 10126 Torino, Italy and Olive Miller Laboratory [R.G.H.C.],Murdoch Institute, Royal Children's Hospital, Vicroria,Australia 3052 ABSTRACT. Some cases of primary hyperphenylalanine- PKU to describe some cases clinically unresponsive to a Phe- mia are not caused by the lack of phenylalanine hydroxyl- restricted diet and later shown to be due to BH4 deficiency ase, but by the lack of its cofactor tetrahydrobiopterin. ( 1-4). These patients are not clinically responsive to a phenylal- By analyzing all the essential components of the complex anine-restricted diet, but need specific substitution therapy. hydroxylation system of aromatic amino acids, it became appar- Thus, it became necessary to examine all newborns ent that a defect in the BH4 recycling enzyme DHPR (EC screened as positive with the Guthrie test for tetrahydro- 1.66.99.7) and two defects in BH4 synthetic pathway enzymes, biopterin deficiency. Methods based on urinary pterin or guanosine triphosphate cyclohydrolase I (EC 3.5.4.16) and 6- on specific enzyme activity measurements are limited in PPH4S, may lead to cofactor deficiency resulting in HPA and in their availability, and the simplest method, based on the impaired production of dopamine and serotonin (5-7).
    [Show full text]
  • Coronary Microvascular Dysfunction in CAD: Consequences and Potential Therapeutic Applications
    4 Coronary Microvascular Dysfunction in CAD: Consequences and Potential Therapeutic Applications Alan N. Beneze1, Jeffrey M. Gold4 and Betsy B. Dokken1,2,3 1University of Arizona College of Medicine 2University of Arizona Department of Medicine, Section of Endocrinology 3University of Arizona Sarver Heart Center 4Inpatient Physicians Consultants, Tucson, Arizona USA 1. Introduction Substantial research and clinical effort has been directed toward the understanding, identification and management of coronary artery disease (CAD). As a result, the processes of cholesterol accumulation and inflammation that lead to large vessel occlusions have been fully elucidated. In contrast to those with CAD, many patients have symptoms of angina and reductions in coronary flow reserve despite normal coronary angiography of the large epicardial arteries. In this situation the vessels that limit flow to myocardium are the more distal epicardial prearterioles and intramyocardial arterioles – vessels typically too small to be directly visualized by conventional coronary angiography. These vessels comprise the coronary microcirculation. Coronary microvascular dysfunction (CMVD), in contrast to CAD, continues to be poorly understood and difficult to manage. In addition, the presence of CMVD can be a confounding factor in the management of patients with CAD. 2. Anatomy and physiology of the coronary microcirculation The coronary arterial network is generally divided into three sequential morphological zones. The large epicardial coronary arteries decrease in diameter from 2-5 to 500 microns as they branch off of the aorta and travel distally along the epicardium. Distal to the large coronary arteries are epicardial pre-arterioles that decrease in diameter from 500 to 100 microns. Finally, the pre-arterioles give rise to intramyocardial arterioles that measure 100 microns or less in diameter.
    [Show full text]
  • Example of How Amehsi Specification Indicators Can Be Mapped to Health
    Example of how Amehsi Specification Indicators can be Mapped to Health Conditions and Health Statuses The information presented here may be covered by copyrights and patents Some of the Amehsi Factors which can be alleviated using Amehsi Specification Recommendations and Demise Oncology Leukemia Lymphoma HIV Information. This document may be protected by copyrights and patents Choline Deficiency or Circumstantial Choline Deficiency from upregulated Choline Kinase Pathway or Kennedy Pathway Factors Causal Causal Causal Causal Causal Homocysteine Required as Symptom, Correlated and Incipiently Causal, inhibits PEMT Required Causal Causal Causal S-Adenosyl Homocysteine Downregulat Required as Symptom, Correlated and Incipiently Causal, inhibits PEMT Required Causal ed PEMT Causal Trimethylamine-N-Oxide Causal, inhibits PEMT Causal Causal Causal Incipient Enabler Choline Kinase Upregulation Causal Required Required uNOS Required Required as both PEMT1 or PEMT2 since Diagnostic Assay sometimes does not report if one of these is inhibited while the other is not. PEMT produces a Monomethylethanolamine that Phosphatidylethanolamine deteriorates PCBs, Dioxins, Aryl Methyltransferase Downregulation Cyclic Hydrocarbons, Alkyl Halides, other Carcinogens and produces Serine Proteases that catabolize Amino acids to thier most basic structures, resulting in purified cellular environment and embryonic Causal cellular plasticity Required Required Required Inducible Nitric Oxide Synthase, Required, inhibits PEMT and upregulated Choline kinase, as well as
    [Show full text]
  • Enos-Uncoupling in Age-Related Erectile Dysfunction
    International Journal of Impotence Research (2011) 23, 43–48 & 2011 Macmillan Publishers Limited All rights reserved 0955-9930/11 www.nature.com/ijir ORIGINAL ARTICLE eNOS-uncoupling in age-related erectile dysfunction JM Johnson, TJ Bivalacqua, GA Lagoda, AL Burnett and B Musicki Department of Urology, The Johns Hopkins University, Baltimore, MD, USA Aging is associated with ED. Although age-related ED is attributed largely to increased oxidative stress and endothelial dysfunction in the penis, the molecular mechanisms underlying this effect are not fully defined. We evaluated whether endothelial nitric oxide synthase (eNOS) uncoupling in the aged rat penis is a contributing mechanism. Correlatively, we evaluated the effect of replacement with eNOS cofactor tetrahydrobiopterin (BH4) on erectile function in the aged rats. Male Fischer 344 ‘young’ (4-month-old) and ‘aged’ (19-month-old) rats were treated with a BH4 precursor sepiapterin (10 mg/kg intraperitoneally) or vehicle for 4 days. After 1-day washout, erectile function was assessed in response to electrical stimulation of the cavernous nerve. Endothelial dysfunction (eNOS uncoupling) and oxidative stress (thiobarbituric acid reactive substances, TBARS) were measured by conducting western blot in penes samples. Erectile response was significantly reduced in aged rats, whereas eNOS uncoupling and TBARS production were significantly increased in the aged rat penis compared with young rats. Sepiapterin significantly improved erectile response in aged rats and prevented increase in TBARS
    [Show full text]
  • Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 2001 Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis. Carlos Roberto fontes Pinto Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Pinto, Carlos Roberto fontes, "Effects of Nitric Oxide Synthase Inhibitors on Equine and Bovine Follicular Dynamics and Steroidogenesis." (2001). LSU Historical Dissertations and Theses. 430. https://digitalcommons.lsu.edu/gradschool_disstheses/430 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,537,992 B2 Parker (45) Date of Patent: Mar
    USOO6537992B2 (12) United States Patent (10) Patent No.: US 6,537,992 B2 Parker (45) Date of Patent: Mar. 25, 2003 (54) REGULATION OF ORGANIC NITRATE Erik Stroes, et al., “Tetrahydrobiopterin Restores Endothe TOLERANCE lial Function in Hypercholesterolemia', J. Clin. Invest., vol. 99, No. 1, Jan., 1997, pp. 41–46. (75) Inventor: John D. Parker, 15 Oakly Place, Jørn Bech Laursen, et al., “Nitrate Tolerance Impairs Nitric Toronto, Ontario (CA), M2P 2G3 Oxide-Mediated Vasodilation in Vivo”, Cardiovascular Research, vol. 31, (1996) pp. 814-819. (73) Assignee: John D. Parker (CA) Chao Han, et al., “Pharmacokinetics of Nitroglycerin and Its * Y NotOtice: Subjubject to anyy disclaimer,disclai theh term off thisthi Four Metabolites During Nitroglycerin Transdermal Admin patent is extended or adjusted under 35 istration', Biopharmaceutics & Drug Disposition, Vol. 15, U.S.C. 154(b) by 0 days. (1994) pp. 179–183. Georgette M. Buga, et al., “Negative Feedback Regulation of Endothelial Cell Function by Nitric Oxide', Circulation (21) Appl. No.: 09/754,196 Research, vol. 73, No. 5, Nov., 1993, pp. 808–812. (22) Filed: Jan. 5, 2001 Frank W. Lee, et al., “Pharmacokinetics and Pharmacody namics of Nitroglycerin and Its Dinitrate Metabolites in (65) Prior Publication Data Conscious Dogs: Intravenous Infusion Studies”, J. of Pharm. US 2002/009 1126 A1 Jul. 11, 2002 and Biopharm., vol. 21, No. 5, (1993) pp. 533–550. Walter E. Haefeli, et al., “Comparison of Vasodilatory (51) Int. Cl." .............................................. A61K 31f495 Responses to Nitroglycerin and its Dinitrate Metabolites in (52) U.S. Cl. ....................................................... 514/249 Human Veins”, Clin. Pharmacol. Ther., vol. 52, No.
    [Show full text]
  • Effects of Rosiglitazone on Nitroglycerin
    EFFECTS OF ROSIGLITAZONE ON NITROGLYCERIN- INDUCED ENDOTHELIAL DYSFUNCTION by Kumar Perampaladas B.Sc. A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Pharmacology and Toxicology University of Toronto Supervisor: John D. Parker, MD, FRCP(C) © Copyright by Kumar Perampaladas (2010) Effects of Rosiglitazone on Nitroglycerin-Induced Endothelial Dysfunction Kumar Perampaladas, Master of Science, 2010 Graduate Department of Pharmacology and Toxicology, University of Toronto ABSTRACT Sustained nitroglycerin (GTN) therapy impairs endothelial function in healthy volunteers and patients with cardiovascular disease, caused by an increase in vascular oxidative stress. This study aims to estimate the effect of rosiglitazone on vascular endothelial function in healthy volunteers continuously dosed to transdermal GTN (0.6mg/hr) for 7 days. To assess endothelial function, forearm blood flow was measured by venous occlusion strain-gauge plethysmography in response to intra-brachial infusions of acetylcholine. GTN-treated subjects experienced significant attenuation of endothelium-dependent responses to acetylcholine (p<0.05; compared to placebo), but was reversed with vitamin C (p=ns; compared to placebo). Endothelium-dependent responses to acetylcholine were blunted in groups randomized to rosiglitazone alone (p<0.05; compared to placebo) and rosiglitazone + GTN (p<0.05 compared to placebo). Interestingly, this effect was not modified by vitamin C. In conclusion, rosiglitazone impairs endothelial function and concurrent therapy with rosiglitazone does not attenuate the adverse effects of transdermal GTN on the vasculature. ii ACKNOWLEDGEMENTS First and foremost, I would like to thank my supervisor Dr. John Parker for his continuous support during my Master’s Program. Dr.
    [Show full text]
  • Tetrahydrobiopterin: a Novel Antihypertensive Therapy
    Journal of Human Hypertension (2008) 22, 401–407 & 2008 Nature Publishing Group All rights reserved 0950-9240/08 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Tetrahydrobiopterin: a novel antihypertensive therapy M Porkert1, S Sher1, U Reddy1, F Cheema1, C Niessner1, P Kolm2, DP Jones3, C Hooper4, WR Taylor1, D Harrison1 and AA Quyyumi1 1Division of Cardiology, Emory University, Atlanta, GA, USA; 2Christiana Care Center for Outcomes Research, Newark, DE, USA; 3General Clinical Research Center, Emory University, Atlanta, GA, USA and 4Centers for Disease Control, Atlanta, GA, USA Tetrahydrobiopterin (BH4) is a cofactor for the nitric after 5 weeks and persisted for the 8-week study period. oxide (NO) synthase enzymes, such that its insuffi- Study 2: subjects given 400 mg BH4 had decreased ciency results in uncoupling of the enzyme, leading to systolic (P ¼ 0.03) and mean BP (P ¼ 0.04), with a peak release of superoxide rather than NO in disease decline of 16±19 mm Hg (P ¼ 0.04) at 3 weeks. BP states, including hypertension. We hypothesized that returned to baseline 4 weeks after discontinuation. oral BH4 will reduce arterial blood pressure (BP) and Significant improvement in endothelial function was improve endothelial function in hypertensive subjects. observed in Study 1 subjects and those receiving Oral BH4 was given to subjects with poorly controlled 400 mg BH4. There was no significant change in subjects hypertension (BP 4135/85 mm Hg) and weekly measure- given the 200 mg dose. This pilot investigation indicates ments of BP and endothelial function made. In Study 1, 5 that oral BH4 at a daily dose of 400 mg or higher has À1 À1 or 10 mg kg day of BH4 (n ¼ 8) was administered a significant and sustained antihypertensive effect orally for 8 weeks, and in Study 2, 200 and 400 mg of in subjects with poorly controlled hypertension, an BH4 (n ¼ 16) was given in divided doses for 4 weeks.
    [Show full text]
  • Changes in the Dimeric State of Neuronal Nitric Oxide Synthase
    Changes in the Dimeric State of Neuronal Nitric Oxide Synthase Affect the Kinetics of Secretagogue-Induced Insulin Response Anne-Dominique Lajoix,1,2 Martine Pugnie`re,2 Franc¸oise Roquet,2 Jean-Claude Mani,2 Samuel Dietz,1,2 Nathalie Linck,2 Fleur Faurie,2 Ge´rard Ribes,2 Pierre Petit,2 and Rene´ Gross2 2ϩ We previously showed that pancreatic ␤-cells express a Ca -calmodulin–independent inducible NOS (iNOS) (1). As neuronal isoform of nitric oxide synthase (nNOS) that homodimers (2), NOSs produce NO through the transfer of controls insulin secretion by exerting two enzymatic NADPH-derived electrons from the reductase domain to the activities: nitric oxide (NO) production and cytochrome heme of the adjacent oxygenase domain, so that the heme c reductase activity. We now bring evidence that two iron binds O2 and catalyzes the mono-oxygenation of the inhibitors of nNOS, N-␻-nitro-L-arginine methyl ester substrate arginine. Accordingly, different classes of NOS (L-NAME) and 7-nitroindazole (7-NI), increase glucose- inhibitors have been developed to assess the functional role induced insulin secretion but affect ␤-cell function dif- of these enzymes and include substrate-based inhibitors such ferently. In the presence of L-NAME, insulin response is monophasic, whereas 7-NI preserves the normal bipha- as arginine analogs (3–5) and imidazole derivatives (6), sic secretory pattern. In addition, the alterations of which compete with the substrate binding, flavoprotein (7), ␤-cell functional response induced by the inhibitors also calmodulin inhibitors (8), and finally pterin antagonists such differ by their sensitivity to a substitutive treatment as indazole agents (9).
    [Show full text]
  • Decreased Expression of Intestinal P-Glycoprotein Increase the Analgesic Effects of Oral Morphine in a Streptozotocin-Induced Diabetic Mouse Model
    Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Received; June 2, 2011 Published online; August 30, 2011 Accepted; August 12, 2011 doi; 10.2133/dmpk.DMPK-11-RG-051 Decreased expression of intestinal P-glycoprotein increase the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model Ayaka Nawa1, Wakako Fujita-Hamabe1, Shiroh Kishioka2, and Shogo Tokuyama1＊ 1 Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586, Japan 2 Department of Pharmacology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8059, Japan 1 Copyright C 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Running title page: P-gp increase the analgesic effects of oral morphine *Correspondence to: Shogo Tokuyama Ph. D. Department of Clinical Pharmacy, School of Pharmaceutical Sciences Kobe Gakuin University 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586, Japan Tel./Fax: +81-78-974-4780 Email: [email protected] The number of text pages; 31 The number of figures; 7 2 Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE SUMMARY Morphine is one of the strongest analgesics and commonly used for the treatment of chronic pain. The pharmacokinetic properties of morphine are, in part, modulated by P-glycoprotein (P-gp). We have previously reported that intestinal P-gp expression levels are influenced via the activation of inducible nitric oxide synthase (iNOS) in streptozotocin (STZ)-induced diabetic mice. Herein, we examined the analgesic effects of orally administrated morphine and its pharmacokinetic properties under diabetic conditions, specifically we focusing on the involvement of intestinal P-gp in a type 1 diabetic mouse model.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0336945 A1 Rustomjee Et Al
    US 2013 0336945A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0336945 A1 Rustomjee et al. (43) Pub. Date: Dec. 19, 2013 (54) STABLE COMPOSITIONS OF (30) Foreign Application Priority Data TETRAHYDROBOPTERN Mar. 1, 2011 (IN) ........................... 573/MUM/2011 (71) Applicants: Maharukh Tehmasp Rustomjee, Mumbai (IN); Anilkumar Surendrakumar Gandhi, Mumbai (IN) Publication Classification (72) Inventors: Maharukh Tehmasp Rustomjee, (51) Int. Cl. Mumbai (IN); Anilkumar A 6LX3/59 (2006.01) Surendrakumar Gandhi, Mumbai (IN) (52) U.S. Cl. (73) Assignee: RUBICON RESEARCH PRIVATE CPC .................................... A6 IK3I/519 (2013.01) LIMITED, MUNBAI (IN) USPC .......................................... 424/94.1: 514/249 (21) Appl. No.: 14/002,313 (57) ABSTRACT (22) PCT Filed: Mar. 1, 2013 The present invention relates to stable pharmaceutical com (86). PCT No.: PCT/IB12/SO959 positions of tetrahydrobiopterin and processes for producing Such compositions. Particularly the present invention relates S371 (c)(1), to stable pharmaceutical compositions comprising tetrahy (2), (4) Date: Aug. 29, 2013 drobiopterin and at least one stabilizing agent. US 2013/0336945 A1 Dec. 19, 2013 STABLE COMPOSITIONS OF unpalatable. Further the strict regimen of dietary protein is TETRAHYDROBOPTERN practically impossible for patients of all ages to adhere to in daily life. FIELD OF THE INVENTION 0006 Thus there remains a need to obviate the dietary restrictions and replace or Supplement the same with oral 0001. The present invention relates to stable compositions treatment by providing an oral composition of tetrahydro of tetrahydrobiopterin and processes for producing Such com biopterin. positions. Particularly the present invention relates to stable 0007 Further BH4-responsive PAH deficiency has also compositions comprising sapropterin or pharmaceutically been diagnosed as a variant of hyperphenylalaninemia or acceptable salts thereof and at least one stabilizing agent.
    [Show full text]